{"id":"ccnu","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (thrombocytopenia, leukopenia)"},{"rate":"40-60","effect":"Nausea and vomiting"},{"rate":null,"effect":"Cumulative bone marrow toxicity"},{"rate":null,"effect":"Secondary malignancy"},{"rate":null,"effect":"Pulmonary fibrosis (with cumulative dose)"},{"rate":"10-20","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL514","moleculeType":"Small molecule","molecularWeight":"233.70"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CCNU belongs to the nitrosourea class of chemotherapy drugs and works by alkylating DNA, forming covalent bonds that cross-link the DNA double helix. This prevents DNA replication and transcription, leading to apoptosis in rapidly dividing cancer cells. It is lipophilic and can cross the blood-brain barrier, making it particularly useful for brain tumors.","oneSentence":"CCNU (lomustine) is a nitrosourea alkylating agent that cross-links DNA strands, preventing cell replication and inducing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:01.696Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Brain tumors (glioblastoma, high-grade gliomas)"},{"name":"Hodgkin lymphoma"},{"name":"Non-Hodgkin lymphoma"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT06325683","phase":"PHASE2","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-11-08","conditions":"Progressive Glioblastoma, Recurrent Glioblastoma","enrollment":184},{"nctId":"NCT06816134","phase":"PHASE2","title":"Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-01-30","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell","enrollment":48},{"nctId":"NCT07100730","phase":"PHASE3","title":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-11-02","conditions":"Neoplastic Disease, Glioblastoma, Glioblastoma (GBM)","enrollment":50},{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT05382338","phase":"PHASE3","title":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-02-20","conditions":"Childhood Medulloblastoma","enrollment":225},{"nctId":"NCT02724579","phase":"PHASE2","title":"Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-11-17","conditions":"Medulloblastoma","enrollment":45},{"nctId":"NCT05904119","phase":"PHASE3","title":"Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2024-03-15","conditions":"First Progression of Glioblastoma","enrollment":411},{"nctId":"NCT05095376","phase":"PHASE3","title":"Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-28","conditions":"Glioblastoma, Gliosarcoma","enrollment":265},{"nctId":"NCT05331521","phase":"PHASE3","title":"A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).","status":"RECRUITING","sponsor":"University Hospital Heidelberg","startDate":"2021-04-07","conditions":"Oligodendroglioma","enrollment":406},{"nctId":"NCT04702581","phase":"PHASE3","title":"A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-12-07","conditions":"Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion","enrollment":280},{"nctId":"NCT02444000","phase":"PHASE3","title":"gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-22","conditions":"Anaplastic Gliomas With 1p/19q Codeletion","enrollment":280},{"nctId":"NCT00887146","phase":"PHASE3","title":"Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Brain and Central Nervous System Tumors","enrollment":305},{"nctId":"NCT04049669","phase":"PHASE2","title":"Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG","status":"ACTIVE_NOT_RECRUITING","sponsor":"Theodore S. Johnson","startDate":"2019-10-02","conditions":"Glioblastoma, Medulloblastoma, Ependymoma","enrollment":130},{"nctId":"NCT02066220","phase":"PHASE2, PHASE3","title":"International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2014-06","conditions":"Brain Tumors","enrollment":360},{"nctId":"NCT01582269","phase":"PHASE2","title":"A Study in Recurrent Glioblastoma (GB)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04-26","conditions":"Glioblastoma","enrollment":158},{"nctId":"NCT05902169","phase":"PHASE3","title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"CarThera","startDate":"2024-01-29","conditions":"Glioblastoma, Recurrent Glioblastoma, GBM","enrollment":560},{"nctId":"NCT04402073","phase":"PHASE2","title":"Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2022-11-11","conditions":"Medulloblastoma","enrollment":20},{"nctId":"NCT07145112","phase":"PHASE1","title":"Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-10-01","conditions":"Glioblastoma","enrollment":20},{"nctId":"NCT03970447","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2019-07-30","conditions":"Glioblastoma","enrollment":1280},{"nctId":"NCT03149575","phase":"PHASE3","title":"VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM","status":"TERMINATED","sponsor":"DelMar Pharmaceuticals, Inc.","startDate":"2017-10-27","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioma","enrollment":2},{"nctId":"NCT04863950","phase":"PHASE2","title":"Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-05-25","conditions":"Glioblastoma","enrollment":25},{"nctId":"NCT06177964","phase":"PHASE2","title":"Lerapolturev (PVSRIPO) in GBM","status":"RECRUITING","sponsor":"Darell Bigner","startDate":"2024-07-15","conditions":"Recurrent Supratentorial Glioblastoma","enrollment":92},{"nctId":"NCT07120984","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma","status":"NOT_YET_RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2026-01-30","conditions":"Glioma","enrollment":52},{"nctId":"NCT04135807","phase":"EARLY_PHASE1","title":"Implantable Microdevice In Primary Brain Tumors","status":"RECRUITING","sponsor":"Oliver Jonas","startDate":"2020-03-03","conditions":"Grade II Glioma, Grade III Glioma, Grade IV Glioma","enrollment":12},{"nctId":"NCT02986178","phase":"PHASE2","title":"Lerapolturev in Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"Istari Oncology, Inc.","startDate":"2017-06-01","conditions":"Malignant Glioma","enrollment":121},{"nctId":"NCT04762069","phase":"PHASE2","title":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"CNS Pharmaceuticals, Inc.","startDate":"2021-05-18","conditions":"Glioblastoma Multiforme, Adult","enrollment":210},{"nctId":"NCT03632135","phase":"PHASE3","title":"Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Cordgenics, LLC","startDate":"2018-05-20","conditions":"Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT05427136","phase":"","title":"Early Pulmonary Dysfunction in Childhood Cancer Patients","status":"RECRUITING","sponsor":"University Children's Hospital Basel","startDate":"2021-06-01","conditions":"Pulmonary Dysfunction","enrollment":140},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT06879847","phase":"NA","title":"A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-01","conditions":"Relapsed or Refractory Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT06548958","phase":"NA","title":"A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-10","conditions":"Malignant Hematological Diseases","enrollment":40},{"nctId":"NCT03382977","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects","status":"RECRUITING","sponsor":"VBI Vaccines Inc.","startDate":"2017-12-06","conditions":"Glioblastoma Multiforme","enrollment":98},{"nctId":"NCT06809699","phase":"PHASE1","title":"Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"He Huang","startDate":"2022-08-04","conditions":"Hematologic Diseases","enrollment":29},{"nctId":"NCT06809712","phase":"PHASE1","title":"Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"He Huang","startDate":"2022-08-04","conditions":"Hematologic Disease","enrollment":29},{"nctId":"NCT06336291","phase":"PHASE2","title":"A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence","status":"RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2024-05-22","conditions":"Glioblastoma","enrollment":90},{"nctId":"NCT00085735","phase":"PHASE3","title":"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-04-30","conditions":"Medulloblastoma","enrollment":549},{"nctId":"NCT04421378","phase":"PHASE1, PHASE2","title":"A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-06-08","conditions":"Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT06419946","phase":"PHASE3","title":"Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2024-12-01","conditions":"Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma","enrollment":200},{"nctId":"NCT01682187","phase":"PHASE1","title":"A Dose-Escalation Study in Participants With Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-12-15","conditions":"Glioma","enrollment":66},{"nctId":"NCT03678883","phase":"PHASE2","title":"9-ING-41 in Patients with Advanced Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actuate Therapeutics Inc.","startDate":"2019-01-04","conditions":"Cancer, Pancreatic Cancer, Sarcoma","enrollment":350},{"nctId":"NCT06673459","phase":"PHASE3","title":"BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-01","conditions":"T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation","enrollment":430},{"nctId":"NCT03603795","phase":"PHASE2","title":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2018-10-11","conditions":"Acute Myeloid Leukemia","enrollment":110},{"nctId":"NCT03609060","phase":"PHASE2","title":"Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)","status":"ACTIVE_NOT_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2018-08-24","conditions":"Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT00003375","phase":"PHASE2, PHASE3","title":"Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1998-10","conditions":"Brain and Central Nervous System Tumors","enrollment":370},{"nctId":"NCT05304663","phase":"PHASE1","title":"Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression","status":"WITHDRAWN","sponsor":"Philogen S.p.A.","startDate":"2022-06-01","conditions":"Glioblastoma","enrollment":""},{"nctId":"NCT04573192","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression","status":"RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2021-02-19","conditions":"Glioblastoma","enrollment":142},{"nctId":"NCT03412409","phase":"PHASE2","title":"RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2018-02-01","conditions":"Acute Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT06283927","phase":"","title":"The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)","status":"RECRUITING","sponsor":"Jasper Gerritsen","startDate":"2023-01-01","conditions":"Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype","enrollment":464},{"nctId":"NCT04530006","phase":"NA","title":"Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma","status":"UNKNOWN","sponsor":"CancerCare Manitoba","startDate":"2020-12-02","conditions":"Glioblastoma Multiforme","enrollment":20},{"nctId":"NCT03425292","phase":"PHASE1","title":"A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer","status":"COMPLETED","sponsor":"Saint John's Cancer Institute","startDate":"2018-03-01","conditions":"Newly Diagnosed High Grade Glioma","enrollment":49},{"nctId":"NCT03463265","phase":"PHASE2","title":"Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Aadi Bioscience, Inc.","startDate":"2018-08-01","conditions":"High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma","enrollment":62},{"nctId":"NCT03951142","phase":"PHASE2","title":"Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study","status":"UNKNOWN","sponsor":"Kyrre Eeg Emblem","startDate":"2019-10-01","conditions":"Glioblastoma, Brain Metastases","enrollment":165},{"nctId":"NCT05629260","phase":"","title":"The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-12-01","conditions":"Hematological Malignancy","enrollment":300},{"nctId":"NCT05898451","phase":"PHASE2","title":"Effect of Refnot on Immunity in Cancer Patients","status":"COMPLETED","sponsor":"Refnot-Pharm Ltd","startDate":"2009-06-04","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT04933942","phase":"PHASE2","title":"Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2022-09-13","conditions":"First Progression of MGMT Promoter-methylated Glioblastoma","enrollment":""},{"nctId":"NCT05410301","phase":"NA","title":"Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma","status":"WITHDRAWN","sponsor":"Varun Monga, MD","startDate":"2023-04","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":""},{"nctId":"NCT05814731","phase":"NA","title":"Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Haploidentical Stem Cell Transplantation, Conditioning","enrollment":264},{"nctId":"NCT04688021","phase":"PHASE2","title":"A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.","status":"UNKNOWN","sponsor":"Yi Luo","startDate":"2020-12-03","conditions":"Leukemia, Graft-versus-host-disease","enrollment":46},{"nctId":"NCT00100802","phase":"PHASE2","title":"Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-03-21","conditions":"Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma","enrollment":118},{"nctId":"NCT05667402","phase":"NA","title":"Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-01-15","conditions":"Central Nervous System Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":50},{"nctId":"NCT05017610","phase":"EARLY_PHASE1","title":"Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2021-10-20","conditions":"Recurrent Glioblastoma, Recurrent Gliosarcoma","enrollment":""},{"nctId":"NCT01775475","phase":"PHASE2","title":"Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2016-09-15","conditions":"AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma","enrollment":7},{"nctId":"NCT02926222","phase":"PHASE2","title":"Regorafenib in Relapsed Glioblastoma","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2015-11","conditions":"Glioblastoma Multiforme","enrollment":119},{"nctId":"NCT05518383","phase":"PHASE4","title":"B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-05-25","conditions":"Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma, Primary Mediastinal Lymphoma","enrollment":300},{"nctId":"NCT03022578","phase":"PHASE2","title":"Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-11-07","conditions":"IDH Family Wildtype, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma","enrollment":7},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT03412266","phase":"PHASE2","title":"RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-02-01","conditions":"Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT02843230","phase":"","title":"Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-08-01","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT02796261","phase":"PHASE3","title":"Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients","status":"UNKNOWN","sponsor":"Orbus Therapeutics, Inc.","startDate":"2016-07","conditions":"Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma","enrollment":343},{"nctId":"NCT02212574","phase":"EARLY_PHASE1","title":"Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-04-04","conditions":"Medulloblastoma","enrollment":6},{"nctId":"NCT02076152","phase":"NA","title":"FMISO PET Study of Glioblastoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-02","conditions":"Recurrent Glioblastoma","enrollment":11},{"nctId":"NCT02765165","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)","status":"TERMINATED","sponsor":"Proximagen, LLC","startDate":"2016-04","conditions":"Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2)","enrollment":26},{"nctId":"NCT04945096","phase":"PHASE3","title":"Outcomes of Patients After Allo-HSCT With Decitabine and NAC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-07-01","conditions":"Engraft Failure, Relapse, GVHD","enrollment":100},{"nctId":"NCT02869087","phase":"NA","title":"The DESappear Study: Drug Eluting Scaffold","status":"COMPLETED","sponsor":"Elixir Medical Corporation","startDate":"2016-10-10","conditions":"Peripheral Vascular Disease","enrollment":21},{"nctId":"NCT04702048","phase":"PHASE4","title":"Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye","status":"WITHDRAWN","sponsor":"University of Rochester","startDate":"2021-02-01","conditions":"Retinopathy, Diabetic","enrollment":""},{"nctId":"NCT03025893","phase":"PHASE2, PHASE3","title":"A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2018-08-31","conditions":"Glioblastoma Multiforme, Glioblastoma, Adult, Glioblastoma","enrollment":100},{"nctId":"NCT02678975","phase":"PHASE2, PHASE3","title":"Disulfiram in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2017-01","conditions":"Glioma, Glioblastoma","enrollment":88},{"nctId":"NCT01290939","phase":"PHASE3","title":"Bevacizumab and Lomustine for Recurrent GBM","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2011-10","conditions":"Glioblastoma Multiforme, Cognition Disorders, Disability Evaluation","enrollment":592},{"nctId":"NCT01934361","phase":"PHASE1","title":"Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-28","conditions":"Recurrent Glioblastoma Multiforme","enrollment":35},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02343406","phase":"PHASE2","title":"Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-02-17","conditions":"Glioblastoma","enrollment":266},{"nctId":"NCT00058370","phase":"NA","title":"Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-02","conditions":"Brain and Central Nervous System Tumors","enrollment":6},{"nctId":"NCT01614132","phase":"PHASE1, PHASE2","title":"Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2009-01","conditions":"Medulloblastoma","enrollment":33},{"nctId":"NCT01067469","phase":"PHASE2","title":"Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-01","conditions":"Brain Cancer, Glioblastoma","enrollment":83},{"nctId":"NCT03793517","phase":"PHASE2, PHASE3","title":"Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2018-09-01","conditions":"Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse","enrollment":55},{"nctId":"NCT02414165","phase":"PHASE2, PHASE3","title":"The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma","status":"TERMINATED","sponsor":"Tocagen Inc.","startDate":"2015-11-30","conditions":"Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":403},{"nctId":"NCT00004259","phase":"PHASE3","title":"Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-06","conditions":"Brain and Central Nervous System Tumors","enrollment":230},{"nctId":"NCT00295815","phase":"PHASE3","title":"Enzastaurin Versus Lomustine in Glioblastoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-01","conditions":"Glioblastoma","enrollment":397},{"nctId":"NCT03799224","phase":"PHASE2, PHASE3","title":"Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-12-01","conditions":"Stem Cell Transplant Complications, Relapse Leukemia, Refractory Leukemia","enrollment":55},{"nctId":"NCT00031590","phase":"PHASE2","title":"Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma","status":"TERMINATED","sponsor":"Children's Hospital of Philadelphia","startDate":"2001-04","conditions":"Brain Tumors, Central Nervous System Tumors, Medulloblastoma","enrollment":30},{"nctId":"NCT01562197","phase":"PHASE2","title":"A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Bart Neyns","startDate":"2014-04","conditions":"Glioblastoma Multiforme","enrollment":56},{"nctId":"NCT03291314","phase":"PHASE2","title":"Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2017-05-03","conditions":"Recurrent Glioblastoma (WHO-Grade IV Glioma)","enrollment":52},{"nctId":"NCT03758014","phase":"PHASE2, PHASE3","title":"Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients","status":"UNKNOWN","sponsor":"Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd","startDate":"2018-11-27","conditions":"GBM","enrollment":200},{"nctId":"NCT00527657","phase":"PHASE1","title":"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-09","conditions":"Brain Neoplasms, Melanoma","enrollment":17},{"nctId":"NCT00002569","phase":"PHASE3","title":"Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1994-07","conditions":"Brain and Central Nervous System Tumors","enrollment":299},{"nctId":"NCT01860638","phase":"PHASE2","title":"A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-19","conditions":"Glioblastoma","enrollment":296},{"nctId":"NCT01883180","phase":"PHASE4","title":"ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-06","conditions":"Hematopoietic Stem Cell Transplantation, Antithymocyte Globulin, Viral Infection","enrollment":412},{"nctId":"NCT03462095","phase":"NA","title":"De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)","status":"UNKNOWN","sponsor":"National Research Center for Hematology, Russia","startDate":"2017-01","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":350},{"nctId":"NCT01149109","phase":"PHASE3","title":"Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients","status":"COMPLETED","sponsor":"University Hospital, Bonn","startDate":"2010-10","conditions":"Glioblastoma","enrollment":141},{"nctId":"NCT00335075","phase":"PHASE3","title":"Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03-02","conditions":"Glioblastoma, Astrocytoma","enrollment":151}],"_emaApprovals":[],"_faersSignals":[{"count":16,"reaction":"PLATELET COUNT DECREASED"},{"count":15,"reaction":"OFF LABEL USE"},{"count":12,"reaction":"FATIGUE"},{"count":11,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":10,"reaction":"NEUROPATHY PERIPHERAL"},{"count":10,"reaction":"SECOND PRIMARY MALIGNANCY"},{"count":10,"reaction":"WEIGHT DECREASED"},{"count":9,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":9,"reaction":"MUCOSAL INFLAMMATION"},{"count":8,"reaction":"ACUTE HEPATIC FAILURE"}],"_approvalHistory":[],"publicationCount":1684,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CCNU","genericName":"CCNU","companyName":"Radiation Therapy Oncology Group","companyId":"radiation-therapy-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CCNU (lomustine) is a nitrosourea alkylating agent that cross-links DNA strands, preventing cell replication and inducing cancer cell death. Used for Brain tumors (glioblastoma, high-grade gliomas), Hodgkin lymphoma, Non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}